| EQUILLIUM INC. DL-,0001 |
| USA |
| Gesundheit |
| US29446K1060 / A2N7B3 |
| 0FY (Frankfurt) / EQ (NASDAQ) |
| FRA:0FY, ETR:0FY, 0FY:GR, NASDAQ:EQ |
| - |
| https://equilliumbio.com/ |
|
Equillium, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with significant unmet medical needs. The company's lead p..
>Volltext.. |
| 157.27 Mio. EUR |
| 104.83 Mio. EUR |
| - |
| -17.38 Mio. EUR |
| -16.34 Mio. EUR |
| -0.28 EUR |
| 0.59 Mio. EUR |
| 52.6 Mio. EUR |
| - |
| 18.33 |
| -100% |
| -27.56% |
| - |
| - |
| - |
| EQUILLIUM |
| 30.05.26 |